Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

AAGENUS INC

EconomyAI buildoutMarket MapFundsWatchlist
Log in
A

AGENUS INC

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • History
  • News
  • Insider Transactions

News

News

  • Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
    Sep 10, 2026Agenus Inc. Press Releases
  • Agenus to Participate in Upcoming September Investor Conferences
    Aug 31, 2026Agenus Inc. Press Releases
  • Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
    Aug 28, 2026Agenus Inc. Press Releases
  • Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
    Aug 26, 2026Agenus Inc. Press Releases
  • Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
    Aug 6, 2026Agenus Inc. Press Releases
  • Agenus to Provide Second Quarter 2026 Financial Report and Development Update
    Jul 28, 2026Agenus Inc. Press Releases
  • Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
    Jul 17, 2026Agenus Inc. Press Releases
  • Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
    Jul 13, 2026Agenus Inc. Press Releases
  • Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
    Jul 6, 2026Agenus Inc. Press Releases
  • Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
    Jun 25, 2026Agenus Inc. Press Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • History
  • News
  • Insider Transactions
$7.49Close · Oct 6, 2026